XML 25 R14.htm IDEA: XBRL DOCUMENT v3.24.2
STOCKHOLDERS' EQUITY
 6 Months Ended
Jun. 30, 2024
Equity [Abstract]  
STOCKHOLDERS' EQUITY STOCKHOLDERS’ EQUITY
Stockholders’ Equity
The following tables present the changes in stockholders’ equity (in millions):
Three Months Ended June 30, 2024
Common StockAdditional Paid-In CapitalRetained EarningsAccumulated Other Comprehensive LossTotal Intuitive Surgical, Inc. Stockholders’ EquityNoncontrolling Interest in Joint VentureTotal Stockholders’ Equity
SharesAmount
Beginning balance354.7 $0.4 $8,903.0 $5,067.9 $(8.7)$13,962.6 $83.8 $14,046.4 
Issuance of common stock through employee stock plans0.6 — 71.5 — — 71.5 — 71.5 
Shares withheld related to net share settlement of equity awards— — (0.4)(13.1)— (13.5)— (13.5)
Share-based compensation expense related to employee stock plans— — 175.6 — — 175.6 — 175.6 
Net income attributable to Intuitive Surgical, Inc.— — — 526.9 — 526.9 — 526.9 
Other comprehensive income (loss)— — — — (14.8)(14.8)(0.2)(15.0)
Net income attributable to noncontrolling interest in joint venture— — — — — — 4.6 4.6 
Ending balance355.3 $0.4 $9,149.7 $5,581.7 $(23.5)$14,708.3 $88.2 $14,796.5 
Three Months Ended June 30, 2023
Common StockAdditional Paid-In CapitalRetained EarningsAccumulated Other Comprehensive LossTotal Intuitive Surgical, Inc. Stockholders’ EquityNoncontrolling Interest in Joint VentureTotal Stockholders’ Equity
SharesAmount
Beginning balance
350.4 $0.4 $7,928.4 $3,397.4 $(108.5)$11,217.7 $76.5 $11,294.2 
Issuance of common stock through employee stock plans1.0 — 74.6 — — 74.6 — 74.6 
Shares withheld related to net share settlement of equity awards(0.1)— (0.4)(10.5)— (10.9)— (10.9)
Share-based compensation expense related to employee stock plans— — 148.2 — — 148.2 — 148.2 
Net income attributable to Intuitive Surgical, Inc.— — — 420.8 — 420.8 — 420.8 
Other comprehensive income (loss)— — — — 28.7 28.7 (1.1)27.6 
Net income attributable to noncontrolling interest in joint venture— — — — — — 5.2 5.2 
Ending balance
351.3 $0.4 $8,150.8 $3,807.7 $(79.8)$11,879.1 $80.6 $11,959.7 
Six Months Ended June 30, 2024
Common StockAdditional Paid-In CapitalRetained EarningsAccumulated Other Comprehensive LossTotal Intuitive Surgical, Inc. Stockholders’ EquityNoncontrolling Interest in Joint VentureTotal Stockholders’ Equity
SharesAmount
Beginning balance
352.3 $0.4 $8,576.4 $4,743.0 $(12.2)$13,307.6 $89.7 $13,397.3 
Issuance of common stock through employee stock plans3.6 — 251.9 — — 251.9 — 251.9 
Shares withheld related to net share settlement of equity awards(0.6)— (7.0)(233.1)— (240.1)— (240.1)
Share-based compensation expense related to employee stock plans— — 328.4 — — 328.4 — 328.4 
Net income attributable to Intuitive Surgical, Inc.— — — 1,071.8 — 1,071.8 — 1,071.8 
Other comprehensive income (loss)— — — — (11.3)(11.3)(0.6)(11.9)
Cash dividends declared and paid by joint venture
— — — — — — (8.0)(8.0)
Net income attributable to noncontrolling interest in joint venture— — — — — — 7.1 7.1 
Ending balance
355.3 $0.4 $9,149.7 $5,581.7 $(23.5)$14,708.3 $88.2 $14,796.5 
Six Months Ended June 30, 2023
Common StockAdditional Paid-In CapitalRetained EarningsAccumulated Other Comprehensive LossTotal Intuitive Surgical, Inc. Stockholders’ EquityNoncontrolling Interest in Joint VentureTotal Stockholders’ Equity
SharesAmount
Beginning balance
350.0 $0.4 $7,703.9 $3,500.1 $(162.5)$11,041.9 $70.7 $11,112.6 
Issuance of common stock through employee stock plans3.4 — 174.8 — — 174.8 — 174.8 
Shares withheld related to net share settlement of equity awards(0.6)— (6.3)(134.3)— (140.6)— (140.6)
Share-based compensation expense related to employee stock plans— — 294.2 — — 294.2 — 294.2 
Repurchase and retirement of common stock(1.5)— (15.8)(334.2)— (350.0)— (350.0)
Net income attributable to Intuitive Surgical, Inc.— — — 776.1 — 776.1 — 776.1 
Other comprehensive income (loss)— — — — 82.7 82.7 (0.8)81.9 
Net income attributable to noncontrolling interest in joint venture— — — — — — 10.7 10.7 
Ending balance
351.3 $0.4 $8,150.8 $3,807.7 $(79.8)$11,879.1 $80.6 $11,959.7 
Stock Repurchase Program
The Company’s Board of Directors (the “Board”) has authorized an aggregate of $10.0 billion of funding for the Company’s common stock repurchase program (the “Repurchase Program”) since its establishment in March 2009. The most recent authorization occurred in July 2022, when the Board increased the authorized amount available under the Repurchase Program to $3.5 billion, including amounts remaining under previous authorization. As of June 30, 2024, the remaining amount of share repurchases authorized by the Board under the Repurchase Program was approximately $1.1 billion.
The following table summarizes stock repurchase activities (in millions, except per share amounts):
 Three Months Ended June 30,Six Months Ended June 30,
 2024202320242023
Shares repurchased— — — 1.5 
Average price per share$— $— $— $238.1 
Value of shares repurchased$— $— $— $350.0 
Accumulated Other Comprehensive Loss, Net of Tax, Attributable to Intuitive Surgical, Inc.
The components of accumulated other comprehensive loss, net of tax, attributable to Intuitive Surgical, Inc. are as follows (in millions):
 Three Months Ended June 30, 2024
 Gains on Hedge InstrumentsUnrealized Losses on Available-for-Sale SecuritiesForeign Currency Translation Gains (Losses)Employee Benefit PlansTotal
Beginning balance$3.1 $(33.9)$21.6 $0.5 $(8.7)
Other comprehensive income (loss) before reclassifications1.1 5.4 (25.1)— (18.6)
Amounts reclassified from accumulated other comprehensive income3.7 0.1 — — 3.8 
Net current-period other comprehensive income (loss)4.8 5.5 (25.1)— (14.8)
Ending balance$7.9 $(28.4)$(3.5)$0.5 $(23.5)
 Three Months Ended June 30, 2023
 Gains (Losses) on Hedge InstrumentsUnrealized Losses on Available-for-Sale SecuritiesForeign Currency Translation GainsEmployee Benefit PlansTotal
Beginning balance$(0.4)$(116.6)$7.3 $1.2 $(108.5)
Other comprehensive income before reclassifications6.9 13.1 9.6 — 29.6 
Amounts reclassified from accumulated other comprehensive income (loss)(0.9)— — — (0.9)
Net current-period other comprehensive income6.0 13.1 9.6 — 28.7 
Ending balance$5.6 $(103.5)$16.9 $1.2 $(79.8)
Six Months Ended June 30, 2024
Gains (Losses) on Hedge InstrumentsUnrealized Losses on Available-for-Sale SecuritiesForeign Currency Translation Gains (Losses)Employee Benefit PlansTotal
Beginning balance$(2.5)$(29.7)$19.4 $0.6 $(12.2)
Other comprehensive income (loss) before reclassifications5.2 1.1 (22.9)— (16.6)
Amounts reclassified from accumulated other comprehensive income (loss)5.2 0.2 — (0.1)5.3 
Net current-period other comprehensive income (loss)10.4 1.3 (22.9)(0.1)(11.3)
Ending balance$7.9 $(28.4)$(3.5)$0.5 $(23.5)
Six Months Ended June 30, 2023
Gains (Losses) on Hedge InstrumentsUnrealized Losses on Available-for-Sale SecuritiesForeign Currency Translation Gains (Losses)Employee Benefit PlansTotal
Beginning balance$(2.9)$(154.2)$(6.6)$1.2 $(162.5)
Other comprehensive income before reclassifications10.6 50.9 23.5 — 85.0 
Amounts reclassified from accumulated other comprehensive income (loss)(2.1)(0.2)— — (2.3)
Net current-period other comprehensive income8.5 50.7 23.5 — 82.7 
Ending balance$5.6 $(103.5)$16.9 $1.2 $(79.8)
The tax impacts for amounts recognized in other comprehensive income (loss) before reclassifications were as follows (in millions):
Three Months Ended June 30,Six Months Ended June 30,
Available-for-sale securities2024202320242023
Income tax benefit (expense) for net gains (losses) recorded in other comprehensive income (loss)
$(1.6)$(3.7)$(0.3)$(14.6)
The tax impacts for amounts recognized in other comprehensive income (loss) before reclassifications for hedge instruments, foreign currency translation gains (losses), and employee benefit plans for the three and six months ended June 30, 2024, and 2023, were not material to the Company’s Financial Statements. The tax impacts for amounts reclassified from accumulated other comprehensive loss relating to hedge instruments, available-for-sale securities, foreign currency translation gains (losses), and employee benefit plans for the three and six months ended June 30, 2024, and 2023, were not material to the Company’s Financial Statements.